Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration highlights Hengrui Pharma's successful use of the NewCo model to achieve another out-licensing deal","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Agreement grants Braveheart Bio exclusive global rights to develop, manufacture and commercialize HRS-1893 outside of Mainland China, the Hong Kong SAR, the Macao SAR and Taiwan Region","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"HRS-1893 currently in Phase 3 clinical trial in China for treatment of obstructive hypertrophic cardiomyopathy (oHCM)","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":433,"olType":false},{"type":"text","content":"SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH；01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential. Braveheart Bio is a newly launched, U.S.-based biotechnology company focused on cardiovascular disease with a consortium of lead investors that includes Forbion, OrbiMed, and others.","length":590,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Hengrui Pharma has granted Braveheart exclusive rights to develop, manufacture and commercialize HRS-1893 worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, and Taiwan Region. Braveheart will make an upfront payment of $65 million (consisting of $32.5 million in cash and $32.5 million in Braveheart shares) and a near-term payment of up to $10 million upon technology transfer completion, totaling $75 million. Hengrui Pharma is eligible to receive potential development and commercial milestone payments of up to $1.013 billion, in addition to related royalties based on the net sales.","length":641,"tagName":"p"},{"type":"text","content":""This marks the second time in less than 18 months that Hengrui Pharma has partnered with leading international investment institutions and leveraged the NewCo model in our efforts to ensure our innovation benefits patients worldwide," said Frank Jiang, MD, PhD, Executive Vice President and Chief...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A